Observational study of 228 #PsA pts Rx biologics, either early (<2yrs; mean 6 mos) vs later (mean 3.6 yrs). Groups were balanced in all parameters; after 6 mos no diff in DAPSA50 or PASI75 response. Biologics work regardless of when started. https://t.co/ZCDR8l2CsI https://t.co/PHgtgZu12G

Treatment for Obesity and Inflammation, but at what Cost? https://t.co/v87FxQqrAv https://t.co/Oonrexyp0F

Obesity & Biologic Treatment Response Prepared for "The Obesity Imperative" campaign. https://t.co/72TFW6BWgG https://t.co/XWFWoH2D33

Worldwide the Sjögren’s disease market size was valued at approximately $1 billion USD in 2025 and is projected to reach nearly $10 billion USD by 2036 (with annual growth of 26.2% during the forecast period from 2026 to 2036). https://t.co/kxwftpIDeo https://t.co/RnEbzqFi2W

QD Clinic: Managing Muscle and Fat Loss with GLP-1s Dr. David Liew, Melbourne, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign presented in September 2026. https://t.co/t9uD7TGKjZ https://t.co/BzE1m04E2s

ARthritis & CAncer (ARCA) is Spanish retro study of 728 #RA pts w/ Hx of CA & Rx w/ biologics. W/ F/U of 11 022 yrs, new/recurrent CA was not incr (7.3/1000PYs) & = Pts Rx w/ csDMARDs (HRs 0.94; 0.73,1.21) & not incr w/ TNFi (0.94), IL-6i (1.03), CD20i (0.81), JAKi (0.6), ABA https://t.co/UUWlsaYV0Z

Mediterranean Diet Lowers Incident Rheumatoid Arthritis Risk The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of https://t.co/9GhEwXuCEI

Bringing TOGETHER-PsA Into Clinical Practice The TOGETHER-PsA trial provides prospective evidence supporting an integrated approach to PsA and weight management, reinforcing the importance of addressing both inflammatory disease activity and metabolic health as part of https://t.co/WmF4mdxDWR

GCA international survey of 155 specialists (rheums 51%; ophthal 33%). w/ GCA dx, ASA started in only 15%; w/ 69.5% uncertain. w/ visual loss, 93% Rheums, 85% Ophthal Rx w/ IVGC, followed by oral. Uncertainty for IV versus po GC seen in 68.5% https://t.co/sWZQv8yw3u https://t.co/08tdXxDve8

Do biologic Rx lower risk of PsA? Metanalysis (15 studies, 124,138 psoriasis pts, 778K PYrs F/U), showed Biologic use assoc w/ lower risk of PsA (HR 0.54); best for IL-17i (0.65) & IL-12/23 or IL-23i (0.46) vs TNFi. IL-23i superior to IL-17i (HR 0.67) https://t.co/pjZZJ8yq9A https://t.co/yIwQs2FwLW

VA/DoD 2025 Obesity Guidelines Annals of Internal Medicine has published the updated 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines on adult Overweight and Obesity management. This effort involved a multidisciplinary panel https://t.co/ukuKGCHhOf

Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/VfV873Lire

Obesity as a Risk Factor for Rheumatic Diseases https://t.co/zTEHDbTGjb https://t.co/1JuGAfL5oK

The Need for Weight Loss and Weight Gain in the ILD Clinic https://t.co/UaKW9GPJTN https://t.co/QGYblSxbfP